{
    "title": "109_s239",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medicare Enhancements for Needed \nDrugs Act of 2005''.\n\nSEC. 2. GAO STUDIES AND REPORTS ON PRICES OF PRESCRIPTION DRUGS.\n\n    (a) Review and Reports on Retail Prices of Prescription Drugs.--\n            (1) Initial review.--The Comptroller General of the United \n        States shall conduct a review of the retail cost of \n        prescription drugs in the United States during 2000 through \n        2003, with an emphasis on the prescription drugs most utilized \n        for individuals age 65 or older.\n            (2) Subsequent review.--After conducting the review under \n        paragraph (1), the Comptroller General shall continuously \n        review the retail cost of such drugs through April 1, 2006, to \n        determine the changes in such costs.\n            (3) Reports.--\n                    (A) Initial review.--Not later than September 1, \n                2005, the Comptroller General shall submit to Congress \n                a report on the initial review conducted under \n                paragraph (1).\n                    (B) Subsequent review.--Not later than July 1, \n                2006, January 1, 2007, and July 1, 2007, the \n                Comptroller General shall submit to Congress a report \n                on the subsequent review conducted under paragraph (2).\n    (b) Annual GAO Study and Report on Retail and Acquisition Prices of \nCertain Prescription Drugs.--\n            (1) Ongoing study.--The Comptroller General of the United \n        States shall conduct an ongoing study that compares the average \n        retail cost in the United States for each of the 20 most \n        utilized prescription drugs for individuals age 65 or older \n        with--\n                    (A) the average price at which private health plans \n                acquire each such drug;\n                    (B) the average price at which the Department of \n                Defense under the Defense Health Program acquires each \n                such drug;\n                    (C) the average price at which the Department of \n                Veterans Affairs under the laws administered by the \n                Secretary of Veterans Affairs acquires each such drug; \n                and\n                    (D) the average negotiated price for each such drug \n                that eligible beneficiaries enrolled in a prescription \n                drug plan under part D of title XVIII of the Social \n                Security Act, as added by section 101 of the Medicare \n                Prescription Drug, Improvement, and Modernization Act \n                of 2003 (Public Law 108-173), that provides only basic \n                prescription drug coverage have access to under such \n                plans.\n            (2) Annual report.--Not later than December 1, 2007, and \n        annually thereafter, the Comptroller General shall submit to \n        Congress a report on the study conducted under paragraph (1), \n        together with such recommendations as the Comptroller General \n        determines appropriate.\n\nSEC. 3. INCLUSION OF AVERAGE AGGREGATE BENEFICIARY COSTS AND SAVINGS IN \n              COMPARATIVE INFORMATION FOR BASIC MEDICARE PRESCRIPTION \n              DRUG PLANS.\n\n    Section 1860D-1(c)(3) of the Social Security Act (42 U.S.C. 1395w-\n101(c)(3)) is amended--\n            (1) in subparagraph (A)--\n                    (A) in the matter preceding clause (i), by striking \n                ``subparagraph (B)'' and inserting ``subparagraphs (B) \n                and (C)''; and\n                    (B) by adding at the end the following new clause:\n                            ``(vi) Average aggregate beneficiary costs \n                        and savings.--With respect to plan years \n                        beginning on or after January 1, 2007, the \n                        average aggregate costs, including deductibles \n                        and other cost-sharing, that a beneficiary will \n                        incur for covered part D drugs in the year \n                        under the plan compared to the average \n                        aggregate costs that an eligible beneficiary \n                        with no prescription drug coverage will incur \n                        for covered part D drugs in the year.''; and\n            (2) by adding at the end the following new subparagraph:\n                    ``(C) Average aggregate beneficiary costs and \n                savings information only for basic prescription drug \n                plans.--The Secretary shall not provide comparative \n                information under subparagraph (A)(vi) with respect \n                to--\n                            ``(i) a prescription drug plan that \n                        provides supplemental prescription drug \n                        coverage; or\n                            ``(ii) a Medicare Advantage plan.''.\n\nSEC. 4. NEGOTIATING FAIR PRICES FOR MEDICARE PRESCRIPTION DRUGS.\n\n    (a) In General.--Section 1860D-11 of the Social Security Act (42 \nU.S.C. 1395w-111) is amended by striking subsection (i) (relating to \nnoninterference) and by inserting the following:\n    ``(i) Authority To Negotiate Prices With Manufacturers.--\n            ``(1) In general.--In order to ensure that beneficiaries \n        enrolled under prescription drug plans and MA-PD plans pay the \n        lowest possible price, the Secretary shall have authority \n        similar to that of other Federal entities that purchase \n        prescription drugs in bulk to negotiate contracts with \n        manufacturers of covered part D drugs, consistent with the \n        requirements and in furtherance of the goals of providing \n        quality care and containing costs under this part.\n            ``(2) Mandatory responsibilities.--The Secretary shall be \n        required to--\n                    ``(A) negotiate contracts with manufacturers of \n                covered part D drugs for each fallback prescription \n                drug plan under subsection (g); and\n                    ``(B) participate in negotiation of contracts of \n                any covered part D drug upon request of an approved \n                prescription drug plan or MA-PD plan.\n            ``(3) Rule of construction.--Nothing in paragraph (2) shall \n        be construed to limit the authority of the Secretary under \n        paragraph (1) to the mandatory responsibilities under paragraph \n        (2).''.\n    (b) Effective Date.--The amendment made by this section shall take \neffect as if included in the enactment of section 101 of the Medicare \nPrescription Drug, Improvement, and Modernization Act of 2003 (Public \nLaw 108-173).\n\nSEC. 5. NAIC REVIEW AND REPORT ON CHANGES IN MEDIGAP POLICIES THAT \n              PROVIDE COVERAGE OF PRESCRIPTION DRUGS CONTAINED IN THE \n              MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND \n              MODERNIZATION ACT OF 2003.\n\n    (a) In General.--The Secretary of Health and Human Services shall \nrequest the National Association of Insurance Commissioners to conduct \na review of the changes to the rules relating to medicare supplemental \npolicies that provide prescription drug coverage contained in \nsubsection (v) of section 1882 of the Social Security Act (42 U.S.C. \n1395ss), as added by section 104(a) of the Medicare Prescription Drug, \nImprovement, and Modernization Act of 2003 (Public Law 108-173).\n    (b) Impact on Medicare Beneficiaries.--The review conducted \npursuant to subsection (a) should focus on the impact the changes \ndescribed in such subsection will have on medicare beneficiaries.\n    (c) Report.--The Secretary shall request the National Association \nof Insurance Commissioners to submit to Congress, by not later than \nJanuary 1, 2006, a report on the review conducted pursuant to \nsubsection (a), together with such recommendations as the National \nAssociation of Insurance Commissioners determines appropriate."
}